Publications


Sponsored
  • Today’s workforce and consumers expect corporations to stay responsive and forward-thinking, echoing voter sentiment in the 2024 US Presidential Election
  • The Election outcome highlights the risks for healthcare and MedTech firms that remain attached to outdated practices in fast-changing markets
  • Traditional executives may lack the digital fluency needed to keep pace with technological and market advancements
  • By embracing varied perspectives and future-oriented strategies, corporations can better align with evolving employee and customer expectations
 
A Wake-Up Call for US Corporations in Fast-Changing Industries

Donald Trump's victory in the November 2024 US Presidential Election suggests lessons - not only for the political sphere but also for corporate leaders, particularly in fast-changing sectors like healthcare and MedTech. While a range of factors contributed to the former president's decisive win, this Commentary focuses on a few themes that stand out for their relevance to business: the weight of legacy issues, the disconnect between leaders and their broader constituencies, and the perils of overconfidence and resistance to change. By addressing core concerns like inflation, economic security, and future opportunities, Trump’s platform resonated with voter priorities, highlighting a gap between traditional leaders and the public. This shift underscores the risks faced by established institutions, both political and corporate, when they fail to respond to legitimate concerns and adapt to dynamic environments.

Much like the political elites, corporate leadership in healthcare and MedTech - especially within conservative firms - risks being disconnected from the shifts of their industry and workforce. In these sectors, rapid innovation and changing market demands are reshaping the landscape. Yet a significant proportion of large companies remain anchored to legacy products and structures, headed by leadership teams largely comprised of US-based senior executives many of whom are nearing retirement. These digital migrants, whose careers were well established before digitalisation, may lack fluency in the latest technological advancements and market shifts, risking a strategic blind spot that leaves them vulnerable to more agile and innovative competitors. Drawing a parallel between the political and corporate worlds, it seems reasonable to suggest that ignoring changing demographics, employee needs, and technological trends introduces risks for corporations just as it does for political entities.

 
In this Commentary

This Commentary highlights how Donald Trump's 2024 Presidential election win serves as a cautionary tale for corporate leaders, especially in fast-evolving sectors like healthcare and MedTech. By drawing parallels between political and corporate spheres, it emphasises the risks for established firms that are slow to adapt to rapid changes in technology, market demands, regulations, and workforce expectations. Through analysis of healthcare trends and leadership dynamics, it provides insights on fostering adaptability, inclusivity, and a forward-thinking culture to stay competitive.
 
Legacy Leadership and the Risks of Inertia in a Fast-Paced Industry

Healthcare and MedTech, more so than many other sectors, are undergoing rapid and transformative changes driven by advancements in biomedical science, artificial intelligence (AI), value-based healthcare, and shifts in care delivery models. New technologies such as AI, machine learning, telehealth, and remote monitoring are driving innovation, as are changing consumer preferences and a growing emphasis on preventive care and patient-centred models. For traditional firms, adapting to these trends is challenging, and demands a readiness to embrace both internal and external changes swiftly and effectively.

Many large MedTech corporations are led by well-established leadership teams composed primarily of American males many of whom have established careers in a more predictable, slower-paced environment. These leaders, often digital immigrants, may lack the skills and cultural agility needed to navigate today’s digital-first landscape. In an industry where start-ups and smaller, more agile companies are increasingly setting the pace, being overly reliant on legacy products and markets and slow to innovate can create significant vulnerabilities.

Just as US voters in November 2024 demonstrated a desire for change by voting for populist policies, there is a growing segment within healthcare and MedTech firms - ranging from early-career employees to mid-level managers - who may feel left behind by leadership that appears out of touch. Such employees may feel that their aspirations, frustrations, and innovative ideas are overlooked, resulting in disillusionment that ultimately stifles creativity and limits the company’s ability to innovate.
 
Misalignment with Market Realities and Employee Expectations

Much like the dissonance between voter priorities and political platforms that played a role in the 2024 American Presidential election, traditional healthcare leaders face the risk of alienating their workforce by not aligning with their evolving expectations. Today’s employees seek flexibility, inclusivity, and growth opportunities, yet many corporate hierarchies remain anchored to legacy mindsets, appearing resistant to the innovation employees value. Amidst inflation, economic pressures, and a rapidly changing healthcare landscape, there is an expectation for companies to prioritise meaningful, sustainable changes over unwavering adherence to past practices.

Such a disconnect can lead to disengagement among skilled and innovative team members who feel side-lined in decision-making processes. In an era where top talent is essential to maintain competitive advantage, traditional corporations must cultivate an inclusive, agile, and future-oriented culture. Failing to address these demands risks losing valuable talent and diminishing the company’s ability to remain competitive.

 
Strategic Blind Spots: The Cost of Ignoring Innovation

Another parallel between the political and corporate spheres lies in the risk of overconfidence in legacy strategies. Just as political analysts underestimated the former President's appeal by relying on inadequate polling methodologies, traditional healthcare companies often misjudge market shifts by relying on legacy product lines and ignoring emerging trends. Such overconfidence in established offerings and processes can be costly in healthcare, where technology-driven innovation has opened new avenues for preventive care, personalised medicine, and outpatient services.

Firms that fail to recognise these shifts risk being blindsided by competitors who are more attuned to the demands of modern consumers. Smaller, more innovative firms are seizing opportunities in areas such as digital health, telemedicine, and wearable technology - offering patients and providers new ways to manage health conditions. These firms are not bound by legacy structures or outdated decision-making processes, allowing them to respond quickly to emerging trends and customer needs.

The trend toward outpatient services and home healthcare is especially significant. As healthcare delivery moves increasingly out of hospitals and into homes and community centres, traditional healthcare companies must rethink their approach to service delivery. A company that remains fixated on hospital-based care or physical products while ignoring digital health services or home-based solutions risks missing the next wave of healthcare innovation.

 
Embracing Change to Bridge the Divide

Trump’s 2024 victory draws attention to the risks of remaining wedded to the past. In his campaign, he demonstrated an ability to connect with voters by focusing on practical solutions to their everyday concerns. Healthcare corporations should consider adopting a similar approach by investing in solutions and services that address the needs of patients and employees. This could involve not only expanding product lines to include digital health tools and preventive care but also restructuring the organisation to make it more agile and responsive.

For corporate leaders, the takeaway is clear: organisations must prioritise responsiveness and agility over rigid adherence to traditional methods. Just as Trump’s victory revealed the risks of political elites being out of touch with public sentiment, corporate leaders risk alienating their workforce and missing growth opportunities by ignoring employee concerns and market trends.

 
Building a Culture of Inclusivity and Innovation
 
In a dynamic healthcare and MedTech landscape, companies need more than just technical expertise and financial acumen to stay competitive; they must foster a culture that values inclusivity, adaptability, and continuous learning. Just as well funded political institutions can lose touch with the needs and concerns of their constituents, corporate leaders risk disconnecting from the aspirations and behaviours of their employees and patients. By aligning more closely with different voices across the organisation - particularly younger, diverse employees and those with digital expertise - companies can tap into a broader spectrum of ideas, unlocking innovation that reinforces their market position.

To achieve this alignment, leaders should actively seek input from employees at all levels, appreciating that crucial insights often emerge from minority voices. This inclusive strategy not only drives engagement and fosters a culture of innovation but also positions the organisation to respond more effectively to both employee and patient needs.
 
The Path Forward: Adaptation as a Core Strategy

The lessons from the American 2024 Election suggest that political and corporate leaders alike must adapt to rapidly changing demographics and expectations. For healthcare and MedTech firms, this means developing strategies that are not only grounded in today’s market realities but also flexible enough to evolve as those realities change.

Adaptation in the healthcare sector could involve investment in new technologies, partnerships with innovative start-ups, and a willingness to experiment with new business models. Companies that can pivot to meet new demands - whether through expanding digital health capabilities, embracing remote monitoring, or exploring personalised medicine - will be better positioned to succeed in a rapidly changing market.

 
Takeaways

The 2024 US Presidential Election results suggest a lesson for corporate leaders: in a fast-paced world, adaptability and responsiveness are key to staying relevant. Just as political leaders risk losing public trust by holding onto past ideas, corporations that resist change undermine their competitive edge and risk alienating both employees and customers. For healthcare and MedTech companies especially, the path forward requires a commitment to innovation, inclusivity, and real-world impact, ensuring resilience in an era defined by continuous transformation.

The stakes are clear: just as political leaders risk losing public confidence by holding onto outdated platforms, companies that cling to legacy practices risk losing valuable talent and market share. Ultimately, the parallel between politics and business underlines a truth: in a world of change, the only sustainable strategy is a commitment to evolution.
view in full page
  • Macroeconomic shocks, including financial crises, geopolitical conflicts, and technological advancements, are creating significant disruptions for healthcare and MedTech companies
  • AI presents transformative opportunities for the industry, but also introduces challenges such as labour displacement and heightened cybersecurity vulnerabilities
  • Ongoing conflicts in Ukraine, the Middle East, and Sudan are already affecting healthcare systems and are likely to cause greater turbulence in the near future
  • Climate change, an intensifying crisis, poses long-term threats to both the healthcare and MedTech sectors

How Macroeconomic Shocks Shape Healthcare and MedTech

In their insightful 2024 publication, Shocks, Crises, and False Alarms, Philipp Carlsson-Szlezak and Paul Swartz offer a timely and thought-provoking perspective of how businesses can navigate the increasingly complex landscape of macroeconomic challenges. Their work questions traditional approaches to risk management, particularly the reliance on deterministic models that fail to capture the full range of possible outcomes. By emphasising the non-linear, interconnected nature of modern crises, the authors encourage businesses to employ more adaptive strategies to survive and thrive in uncertain times.

Their work is especially relevant to healthcare and MedTech companies, which operate in environments defined by constant innovation, regulatory complexity, and the unpredictability of public health. These industries are now facing an era of increased uncertainty, driven by the rapid advancement of artificial intelligence (AI), the threat of infectious diseases, geopolitical instability, and the growing impact of climate change. Such forces influence how healthcare is delivered and how MedTech innovations are developed, necessitating more agile business strategies.

Carlsson-Szlezak and Swartz's critique of traditional risk frameworks is particularly relevant for these sectors. They highlight the importance of flexibility and resilience in responding to rapidly evolving shocks. However, while their work effectively underscores the need for adaptability, it only touches on the impact that the above-mentioned disruptions are already having on healthcare and MedTech. Their insights pave the way for a deeper exploration of these transformative forces, offering a starting point for further discussion.
 

 
The Role of Macroeconomic Shocks in Healthcare and MedTech

Macroeconomic shocks - whether driven by financial crises, political instability, or technological disruptions - create challenges for healthcare and MedTech companies. Events like pandemics, regulatory shifts, and geopolitical conflicts can disrupt global supply chains, alter patient demand, and derail innovation efforts. Traditionally, healthcare companies have managed these risks through strategies like diversification, risk-sharing agreements, and robust contingency planning. Yet, as Carlsson-Szlezak and Swartz suggest, the increasing complexity of the healthcare ecosystem - amplified by rapid technological advancements, shifting regulatory landscapes, and rising patient expectations -makes both predicting and mitigating these shocks increasingly difficult.

The authors provide a nuanced analysis by arguing that not all macroeconomic shocks lead to crises, and that misjudging their potential impact can result in poor decision-making. In healthcare, this balance is important. Overestimating the effects of short-term disruptions, like a new regulatory hurdle, can lead to halted innovation and unnecessary resource allocation. On the other hand, underestimating the long-term consequences of major shocks, such as a global pandemic or sustained geopolitical instability, can jeopardise a company's operations and future viability.

Their thesis emphasises the need for healthcare and MedTech companies to adopt a balanced, forward-looking approach to manage uncertainty. Flexibility and adaptability are key to safeguarding patient care, maintaining profitability, and continuing innovation in the face of unpredictable macroeconomic forces. The authors' framework offers a valuable lens through which companies can better navigate this volatility and build resilience in an ever-changing world.

 
AI: Transforming Healthcare and MedTech

AI stands apart from previous technologies with its abiltiy to learn at exponential rates, autonomously adapt, and make real-time decisions that influence future outcomes. This capability marks it as one of the most impactful shifts in healthcare and MedTech. Already AI is redefining diagnostics, treatment pathways, and operational efficiencies, offering new ways to deliver personalised care, automate administrative tasks, and enhance decision-making. For companies that effectively integrate AI, the potential rewards include improved patient outcomes, reduced costs, and streamlined clinical operations.
However, the adoption of AI also brings challenges, particularly related to job displacement, regulatory uncertainty, and data privacy. Healthcare workers may face redundancy as automation increases, and integration into clinical decision-making raises ethical and legal concerns. Moreover, AI’s dependency on large datasets intensifies concerns about cybersecurity and data breaches, which could lead to financial and reputational damage for companies that fail to secure sensitive patient information. In a highly regulated industry like healthcare, the pace of AI adoption could also outstrip regulatory frameworks, creating uncertainty for companies trying to balance innovation with compliance.
You might also like:

AI: The New Wealth of Nations


Transforming Healthcare with Multimodal AI
For MedTech companies, AI’s power to enhance product development and clinical testing introduces both opportunities and competitive pressures. Early adopters may gain a technological edge, while those slow to integrate it may find themselves left behind in an increasingly automated world.
 
Infectious Diseases: A Persistent Threat

The COVID-19 pandemic exposed the vulnerability of global healthcare systems and MedTech supply chains, compelling companies to rethink their resilience strategies. From shortages in personal protective equipment (PPE) to disrupted clinical trials, the pandemic revealed significant weaknesses throughout the healthcare ecosystem. Yet, COVID-19 is just one example in a broader trend. Other regional health crises - such as Ebola in West Africa, Zika in the Americas, and SARS in Asia – demonstrate how infectious diseases transcend national borders. With the speed and scale of global travel, these outbreaks can spread rapidly, making containment efforts increasingly challenging.

Compounding this issue is the rise of antimicrobial resistance (AMR), exacerbated by climate change, which threatens to fuel the frequency and severity of such disease outbreaks. As temperatures rise and environmental conditions change, new pathogens can emerge, while existing ones may evolve into more treatment-resistant forms. In this context, it seems reasonable to anticipate a rise in pandemics as well as localised infectious disease events.

Infectious diseases not only disrupt healthcare delivery but also change patient behaviour and healthcare priorities. During these flare-ups, demand for critical products, such as diagnostics or respiratory support devices, often surges, while elective procedures and non-urgent care often decline, impacting other revenue streams. Preparing for such volatility requires adaptable supply chains, scalable manufacturing, and flexible healthcare infrastructure. Investment in telehealth, remote patient monitoring, and digital health solutions will be crucial in maintaining continuity of care and mitigating the impacts of future occurences.

 
Geopolitical Shocks: War and Global Healthcare Systems

War and conflict are pervasive forces that continue to shape our world. For example, since its founding in 1776, the United States has been at war or involved in military conflict for 230 out of 248 years, illustrating how deeply entrenched conflict is in modern history. Today's geopolitical tensions, such as the Russo-Ukrainian war, the ongoing hostilities in the Middle East, and the Sudanese civil war have consequences that ripple through global healthcare systems. These conflicts disrupt healthcare supply chains, impede international research collaboration, and hinder the distribution of essential medicines and medical devices, creating challenges that affect patient care across the globe.

For instance, the Middle East conflicts not only strain local healthcare systems but also trigger shortages in medical supplies and overwhelm trauma care facilities. In regions like Sudan, Gaza, and Lebanon, the continuous destruction of hospitals and medical infrastructure further intensifies the already dire healthcare crises, making access to basic medical services nearly impossible for large populations. Attacks on healthcare facilities exacerbate public health emergencies, limit humanitarian aid, and erode long-term health outcomes in conflict zones.

For MedTech and healthcare companies, geopolitical conflicts result in supply chain disruptions, component shortages, price surges, and delays in product development. The reliance on international suppliers for medical devices, equipment, and pharmaceuticals makes these industries vulnerable when supply chains are fractured by war. For example, Israel’s advanced medical manufacturing sector, a critical player in the global healthcare market, faces operational disruptions due to regional instability, directly impacting global exports and limiting the availability of cutting-edge medical technologies.

To safeguard against the risks posed by geopolitical shocks, healthcare companies must go beyond diversifying supply chains; they must also focus on protecting their intellectual assets and R&D capabilities, particularly in regions vulnerable to conflict, such as Israel, renowned for its cutting-edge R&D. This calls for innovative yet reliable strategies, such as duplicating essential intellectual assets in secure locations to safeguard critical R&D and shielding sensitive technologies from potential disruptions or loss. Additionally, establishing multiple manufacturing bases, safeguarding alternative supply sources, and maintaining strategic reserves of critical materials are no longer optional - they are essential steps for safeguarding business continuity and ensuring uninterrupted patient care during crises. As healthcare systems and industries become increasingly interconnected on a global scale, anticipating geopolitical instability, and proactively protecting intellectual assets are vital for guaranteeing that healthcare delivery remains robust, even amid war and conflict.

 
Climate Change and Antimicrobial Resistance: A Deadly Combination

Climate change exacerbates global health challenges, with rising temperatures, extreme weather, and environmental degradation intensifying the spread of infectious diseases and straining healthcare systems. However, a more insidious threat lies in the growing link between climate change and AMR. Higher temperatures and shifting weather patterns can alter ecosystems and promote the spread of resistant bacteria, especially in regions with poor sanitation and overcrowding.
You might also like: 

Antimicrobial Resistance and Climate Change: A Global Crisis

As climate change accelerates the spread of infectious diseases, increased reliance on antibiotics follows, further driving the development of resistance. Warmer temperatures can enhance bacterial growth rates and mutation frequencies, while flooding and water scarcity can spread resistant pathogens through contaminated water sources. Additionally, climate-induced displacement of populations creates conditions for inadequate medical care and overuse of antibiotics, worsening the AMR crisis.
This combination of AMR and climate change creates a vicious cycle, amplifying public health threats and placing pressure on healthcare systems. MedTech companies must respond by developing innovative diagnostics and treatment options that address both environmental impacts and rising resistance. Resilient supply chains, sustainable product designs, and new infection control technologies will be critical in navigating this dual threat. For healthcare providers, climate-adapted infrastructure and infection management roadmaps will be necessary to mitigate the deadly intersection of climate change and AMR.
 
Takeaways

Carlsson-Szlezak and Swartz highlight the importance of adopting flexible, adaptive initiatives in navigating today’s volatile global economy. For healthcare and MedTech companies, the specific challenges posed by AI advancements, the persistent threat of infectious diseases, geopolitical tensions, and the accelerating influences of climate change demand heightened attention. These forces are already impacting healthcare delivery, research methodologies, and MedTech innovation, with their influence expected to grow in the coming years.

To thrive in such an environment, healthcare companies must go beyond short-term resilience. They need to develop robust, long-term strategies that address the interconnected and unpredictable nature of these macroeconomic and geopolitical disruptions. By prioritising investments in evolving technologies, building resilient and diversified supply chains, providing safe havens for threatened intellectual assets in conflict regions, and fostering a culture of continuous innovation, healthcare companies can safeguard their operations and capitalise on emerging opportunities. This proactive approach will enable companies to better navigate future challenges and establish leadership in an increasingly complex and competitive global healthcare landscape. Ultimately, success in this era requires a shift in focus toward sustainable growth, preparedness, and agility in responding to ever-evolving external pressures.
view in full page
  • Ignoring lessons from failures and minority perspectives can result in misguided product development and investments
  • Leaders who only focus on success stories risk survival bias, leading to flawed strategies and poor decisions
  • Learning from failed ventures and former employees can offer insights to avoid common mistakes and ensure long-term success
  • To counter survival bias, companies need to diversify investments, stress-test assumptions, and embrace diverse viewpoints

The Dangers of Survival Bias in Business Strategy: A Conceptual Examination
 
In the competitive world of business, particularly in high-stakes industries like MedTech, leaders often focus on past successes and majority opinions when making strategic decisions. While this might seem logical, it can lead to a phenomenon known as survival bias, which occurs when decision-makers give undue weight to success stories and overlook critical lessons from failures. In a field where both innovation and patient outcomes are at stake, survival bias can be dangerous, fostering a false sense of security that can lead to misaligned strategies in evolving markets.

MedTech companies, for instance, might look to industry giants like Medtronic or Zimmer Biomet as models for success. However, emulating these successes without considering the failures of others can leave companies vulnerable to risks and challenges they have not anticipated. Survival bias blinds leaders to the realities of market misalignments, regulatory hurdles, and poor timing, all of which are important factors of success. By acknowledging both success and failure, executives can create more resilient strategies, which are better equipped to navigate the complexities of the MedTech landscape.

 
In this Commentary

This Commentary explores the risks that survival bias presents to MedTech companies. We examine how an overemphasis on past victories and prevailing opinions can lead to complacency, misguided investments, and missed opportunities for innovation. Importantly, we discuss strategies to mitigate these risks, including broadening decision-making frameworks to embrace the lessons of failure, fostering diverse perspectives, and testing assumptions.
 
The Concept of Survival Bias

During World War II, the Allied forces attempted to improve the survivability of planes returning from bombing missions over Germany. Military engineers began by examining the returning aircraft, documenting where they had been hit and survived. The initial plan was to reinforce the most damaged areas. However, Abraham Wald, a mathematician with Columbia University’s Statistical Research Group, offered a different perspective. Wald observed that the returning planes represented only those that had survived; thus, the damage visible on these aircraft did not provide a complete picture. He reasoned that planes hit in the areas with the least visible damage were likely the ones that had been shot down. His recommendation was to reinforce the undamaged areas to protect against the hits that proved fatal.

This insight is crucial for businesses where focusing only on successes can lead to blind spots. Leaders must be mindful of the lessons from companies and product offerings that failed, as these setbacks often hold the key to understanding the full dynamics of the industry. Ignoring such insights exposes companies to the risk of repeating past mistakes and missing emerging threats.

 
Survival Bias in MedTech Leadership

MedTech leadership often falls into the trap of survival bias, where executives prioritise majority opinions and past successes, side-lining minority viewpoints that could spark innovation. By focusing on replicating legacy product strategies, they risk overlooking the complex market and regulatory factors that initially contributed to those successes.

For example, the triumph of products like Medtronic’s pacemakers and Zimmer Biomet’s orthopaedic implants was not solely due to technical superiority. These companies also navigated intricate regulatory landscapes and evolving patient needs. Relying on outdated strategies without considering current market dynamics can lead to costly misjudgements. The healthcare field, particularly in MedTech, has seen significant shifts in regulation, technology, and patient expectations. Implantable devices that thrived two decades ago may now struggle against advances in minimally invasive procedures or stricter regulations.

Companies that remain tethered to legacy models risk developing products misaligned with today’s needs. Survival bias can also distort investment strategies, causing firms to over-invest in "proven" models while ignoring innovative approaches that could shape the future. This narrow focus may blind companies to transformative opportunities in an ever-changing market.

To avoid these pitfalls, MedTech leaders must be open to diverse perspectives and dissenting opinions. This broader outlook enables firms to better understand risks, seize new opportunities, and stay aligned with evolving market demands. Only by embracing continuous learning and adaptation can companies position themselves for long-term success in a highly regulated and competitive industry.

Learn to Learn from Failure

The key to avoiding survival bias is to recognise that setbacks can offer as much, if not more, insight than success. By studying ventures that failed, companies can gain a deeper understanding of the market dynamics and potential pitfalls they face. For example, ConforMIS’s attempts to transform knee implants through customisation highlight how promising innovations can struggle when faced with regulatory hurdles or scaling issues. Similarly, Theranos’s infamous collapse underscores the dangers of ignoring operational realities while focusing solely on innovation.

Learning from these missteps helps companies avoid repeating similar errors and better anticipate future challenges. This proactive approach not only prevents costly mistakes but also fosters a more comprehensive understanding of the industry.

 
Overcoming Survival Bias: Best Practices

To reduce survival bias and build more resilient strategies, leaders can adopt several best practices:
 
1. Encourage Diverse Perspectives
As Henry Ford once remarked, following majority opinion would have led to faster horses, not cars. True innovation comes from challenging conventional thinking. MedTech enterprises should actively foster a culture that embraces diverse viewpoints and dissenting opinions. Encouraging open debate can reveal blind spots and inspire breakthroughs, while ignoring minority perspectives can lead to poor decision-making and reduced competitiveness. By seeking external feedback from industry outsiders, regulators, healthcare providers, and even competitors, corporations can develop more adaptive strategies that promote long-term growth.

2. Learn from Non-Survivors
Engaging with former employees and examining past failures can provide valuable insights into ingrained behaviours and outdated practices that may be hindering success. Leaders should take the time to confront uncomfortable truths by investigating the reasons behind failed ventures. This approach offers a more realistic view of both internal and external challenges and helps companies identify potential risks before they escalate.

3. Broaden the Dataset
Expanding the scope of analysis to include failures helps companies avoid repeating costly mistakes. In MedTech, studying regulatory setbacks, technical challenges, and market misalignments can guide the development of stronger strategies. A balanced perspective that considers both successes and failures enable companies to navigate the complexities of the healthcare landscape more effectively.

4. Stress-Test Assumptions
Success can breed complacency, leaving companies vulnerable to disruption in fast-evolving sectors like healthcare. To stay ahead, organisations should stress-test their assumptions by running scenario-based simulations that consider various market, technological, and regulatory conditions. This process helps leaders anticipate the impact of factors like new regulations or shifts in patient preferences, allowing for greater agility and resilience in unpredictable environments.

5. Diversify Investments
Focusing too narrowly on a few products or strategies increases risk, particularly in industries prone to rapid change. To minimise this vulnerability, enterprises should diversify their investments across a range of products, technologies, and emerging trends. This approach reduces the impact of underperforming projects or sudden market disruptions, while fostering innovation and exploration of new growth areas.
 
Takeaways

Survival bias skews decision-making by focusing too heavily on successes while overlooking the lessons from failure. In the MedTech industry, where success hinges on a balance of innovation, market dynamics, and regulatory hurdles, this bias can lead to complacency and stagnation. Abraham Wald's seminal work during World War II, where he demonstrated the importance of analysing what was missing - in that case, the planes that did not return - offers a significant reminder. Just as Wald suggested examining overlooked data to improve decision-making, MedTech leaders should not solely celebrate past triumphs but also critically examine failures to avoid blind spots.

By actively seeking out and integrating diverse perspectives, MedTech leaders can foster a more innovative and resilient corporate culture. Stress-testing assumptions, broadening datasets to include failures, and diversifying investments are key strategies for overcoming survival bias. In doing so, companies can develop adaptive strategies that position them for long-term success in a rapidly changing healthcare landscape.
view in full page
  • In September 2024, Lord Darzi’s report warned that England's NHS was nearing collapse
  • Cloning Dr. Devi Shetty’s Narayana Health model could address challenges highlighted in the Darzi report
  • Shetty’s Narayana Health proves that high-quality care can be affordable and accessible to large populations, debunking the idea that higher costs equal better care
  • Western healthcare systems can adopt Shetty’s cost-efficient, tech-driven approach to create sustainable, equitable care, especially for aging populations
  • Narayana Health’s high-volume, low-cost model offers a blueprint for improving efficiency and expanding access to underserved communities
  • Western healthcare leaders can follow Shetty’s example by embracing flexibility and innovation to meet rising demand and limited resources

Revitalising Western Healthcare: Insights from Devi Shetty and Narayana Health


In September 2024, Lord Darzi’s Independent Investigation of the National Health Service (NHS) in England revealed a system on the verge of collapse, where patient confidence in the NHS's capacity to provide timely care is rapidly eroding. Although Darzi, a professor of surgery and former health minister, delivered a thorough and authoritative diagnosis of the NHS’s challenges, his mandate did not extend to offering concrete solutions.

Dr. Devi Shetty and  Narayana Health in India offer a compelling blueprint for Western healthcare reform with their innovative model. By prioritising efficiency, scale, and compassion, Narayana Health has dramatically lowered costs while maintaining world-class standards. Established in 2000, it has grown into a vast network of hospitals, serving millions annually, including an international outpost in the Cayman Islands. Through innovative methods such as economies of scale, telemedicine, and affordable pricing, Narayana Health has succeeded where many Western systems falter - delivering world-class healthcare at a fraction of the cost.

 

The US spends ~$4.5trn annually on healthcare - >17% of GDP - yet millions remain uninsured or underinsured. Meanwhile, the UK's NHS, funded through taxation, faces persistent disparities and long waiting lists. Both systems are burdened by rising costs and unequal access. In contrast, Narayana Health's success shows that affordability and quality care can coexist, pushing Western nations to rethink their costly, inefficient models. Shetty's approach offers a credible case study for addressing healthcare crises in developed nations, aligning with Darzi’s call for future healthcare investments to prioritise services beyond hospitals.

Shetty's work exemplifies how innovation, compassion, and cost-efficiency can transform healthcare delivery, providing hope for more equitable systems in the US, UK, and beyond.

 
In this Commentary
 
This Commentary examines Dr. Devi Shetty's healthcare model at Narayana Health in India as a potential blueprint for reforming Western healthcare. Faced with aging populations, rising costs, and workforce shortages, Western systems could benefit from Shetty’s approach, which emphasises: (i) streamlining operations without compromising quality, (ii) scaling best practices, (iii) expanding access to care, (iv) reducing long-term costs, (v) improving affordability, (vi) leveraging core strengths for better outcomes, (vii) optimising resources, (viii) fostering inclusivity, (ix) embracing innovation, and (x) designing for the future. The Commentary argues that by adopting strategies like process efficiency, task-shifting, and telemedicine, healthcare leaders can cut costs while maintaining high standards of care. It also explores the role of micro-insurance and public-private partnerships in expanding access to underserved communities, advocating for a more flexible, innovative, and inclusive healthcare system in the West.
 
Narayana Health

Founded in 2000 in Bangalore (now Bengaluru), Narayana Health began with a single hospital, Narayana Hrudayalaya, which quickly gained acclaim for its approach to cost-effective cardiac care. Over the next two decades, Narayana Health expanded rapidly across India, building a vast network of multispecialty hospitals, primary care facilities, and its flagship super-specialty cardiac hospital, which is one of the largest in the world. This facility includes 23 dedicated operating rooms, five digital catheterisation laboratories (including a hybrid lab), 200 critical care beds for post-operative patients, and one of the world’s largest paediatric intensive care units. Through economies of scale, telemedicine, and a strong commitment to accessibility, Narayana Health has grown to include >30 hospitals and >7,000 beds, serving millions of patients annually. The organisation marked its international expansion in 2014 with the establishment of Health City Cayman Islands, a state-of-the-art facility offering a wide range of medical services and emerging as a medical tourism hub in the Caribbean. Today, Narayana Health stands as one of India’s largest healthcare providers, known for its large-scale operations, high patient volume, and unwavering dedication to affordable care. This model offers lessons for Western healthcare systems like the US and the UK, where high costs and access barriers persist.

Streamlining Without Sacrificing Quality
Rising healthcare costs in Western systems are driven by advanced technology, expensive treatments, and administrative inefficiencies. Narayana Health demonstrates that affordable, high-quality care is possible through streamlined operations and centralised supply chains. By performing surgeries in high volumes, they lower per-patient costs, proving that efficiency need not compromise quality. Western systems can adopt similar strategies by cutting administrative overhead, standardising protocols, and shifting routine tasks to non-physician staff - driving cost savings without affecting care standards.

Scaling Excellence
Narayana Health’s success stems from its high-volume, low-margin model, which lowers the cost of advanced care. Performing a large number of surgeries enables economies of scale, making quality healthcare accessible to more people. This approach is relevant to Western healthcare, where the cost of individual procedures drives up expenses. Establishing specialised centres for high-demand procedures, such as joint replacements or cardiac surgeries, would concentrate expertise, boost efficiency, and reduce costs, while maintaining high-quality care. This strategy offers a sustainable path to addressing healthcare affordability.

Expanding Access to Care
Devi Shetty played a pivotal role in the success of the Yeshashwini micro-health insurance scheme, which was launched in 2003 to provide affordable healthcare to rural farmers in Karnataka, a state in the southwestern region of India. This visionary programme, driven by Shetty’s leadership, offered low-cost insurance that covered a wide range of medical treatments, including surgeries, for a minimal annual premium. By leveraging Narayana Health’s infrastructure and medical expertise, the scheme made quality healthcare accessible to millions of low-income individuals who had previously lacked coverage.
 

In 2024, Shetty and Narayana Health introduced the the Aditi health insurance plan, designed to address the healthcare needs of India’s growing middle class. The plan provides coverage of up to US$120,000 for surgeries and US$6,000 for medical management, all for an affordable annual premium of just US$120. Aditi goes beyond just financial protection, focusing on preventive care by offering discounted health check-ups and proactive health management. This initiative aims to remove common barriers such as hidden fees and long waiting periods, ensuring timely access to life-saving treatments.

The success of Yeshashwini and Aditi underscores the potential of innovative insurance models to address healthcare gaps worldwide. Western countries, particularly those with underserved populations, could adapt such frameworks to offer affordable coverage for preventive and essential care. Public-private partnerships could be instrumental in scaling these models to meet the needs of low-income and rural populations, helping to bridge healthcare access gaps in more developed nations.


Reducing Long-Term Costs
Preventive care is often underemphasised in Western healthcare systems, leading to higher costs associated with managing chronic diseases and emergency care. Narayana Health’s model, which integrates preventive care with its insurance schemes, offers an example of how a focus on prevention can reduce long-term healthcare costs.

Western healthcare providers and insurers might consider prioritising preventive care within their systems. By emphasising early interventions and preventive measures, healthcare systems can reduce the burden of chronic diseases, which are particularly prevalent among aging populations. This approach improves patient outcomes and reduces the overall cost of care, making healthcare more sustainable in the long run.


Extending Access and Reducing Costs
Narayana Health’s use of technology, particularly telemedicine, is another area where Western healthcare systems can learn lessons. Telemedicine allows Narayana Health to provide care to remote populations at a lower cost, improving access to healthcare for those who might otherwise be underserved.

In Western countries, particularly those with significant rural areas or aging populations, telemedicine has the potential to play a transformative role. By leveraging telehealth, AI-driven diagnostics, and remote monitoring, healthcare systems can extend access to care while containing costs. This is especially important in managing chronic conditions, where regular monitoring and timely interventions can prevent more serious and costly health issues.

 
Leveraging Strengths for Better Care
Narayana Health's collaboration with governments to provide affordable healthcare through insurance programmes highlights the potential of public-private partnerships in improving healthcare delivery. In many Western countries, public healthcare systems are stretched, while private options are often inaccessible for large segments of the population.

Expanding these partnerships could pave the way for hybrid healthcare models that harness the strengths of both sectors. Public systems would focus on core infrastructure and essential services, while private providers could offer specialised care at reduced costs using scalable models like those of Narayana Health. This approach would ease the financial burden on public systems while enhancing the quality and accessibility of care, making advanced medical services affordable for more people. These partnerships offer a strategic solution to the growing healthcare challenges in the West.

Maximising Resources
Public-private partnerships present a promising route to hybrid healthcare models that combine the strengths of both sectors. Public systems could concentrate on providing infrastructure and basic care, while private providers deliver specialised, high-quality treatments at lower costs through efficient, scalable methods, as exemplified by Narayana Health.

This collaboration would alleviate the financial strain on public healthcare systems, which often operate with limited resources, by distributing responsibilities across both sectors. At the same time, it would make advanced medical services more accessible and affordable to a wider population. By blending private sector innovation with the equity of public healthcare, such partnerships could help tackle the complex healthcare challenges facing Western countries today.

Ensuring Inclusivity
A key strength of Devi Shetty’s healthcare model is its dedication to providing affordable care for low-income populations. In Western countries, where income inequality impacts healthcare access, innovative models are needed to extend quality care to underserved communities.

Western healthcare leaders could adopt strategies such as tiered pricing systems or sliding-scale fees based on income, as well as expanding subsidised care for lower-income groups. By prioritising affordability, these initiatives can help reduce health disparities and ensure that more people, regardless of income, receive the care they need. This would improve individual health outcomes and enhance overall public health.

Embracing Change
Shetty’s success stems from his entrepreneurial approach and willingness to disrupt conventional healthcare models. In contrast, Western healthcare systems often resist change, weighed down by entrenched practices and inertia. However, technological advancements and shifting demographics demand greater flexibility.
 

Western healthcare leaders must embrace new business models, pricing structures, and care delivery systems to meet their evolving challenges. Moving from maintaining the status quo to fostering a culture of innovation will be key to improving healthcare accessibility and affordability in aging societies. By encouraging experimentation and change, leaders can better respond to the needs of their populations.

Designing for the Future
Narayana Health’s model stands out for its scalability and adaptability across diverse settings, without sacrificing its core principles of high-volume, affordable care. From a single hospital, it has expanded to multiple locations, consistently maintaining quality and efficiency. This success is driven by streamlined operations, centralised procurement, and a focus on high-volume procedures, which reduce costs per patient.

In contrast, Western healthcare systems struggle with scaling due to bureaucratic hurdles, regulatory barriers, and fragmented services. To address these challenges, scalability should be prioritised in healthcare reforms. Leaders must design systems that can be easily expanded and adapted to meet increasing demand, particularly in underserved areas. By adopting scalable models like Narayana Health’s, Western healthcare can ensure that innovations benefit larger populations, extending advanced care beyond isolated regions and improving access for all.

 
Takeaways

The healthcare model pioneered by Devi Shetty at Narayana Health offers a compelling pathway for reforming Western healthcare systems, which face mounting challenges. The recent Darzi report authoritatively diagnosed the issues confronting NHS England - such as aging populations, rising costs, unacceptable waiting times, and workforce pressures - but did not offer solutions, as this was outside its remit. Shetty's model provides a practical approach that could inform future reforms in the West. Narayana Health demonstrates that high-quality, affordable care can be achieved through innovation and efficiency. By focusing on high-volume procedures, streamlined operations, and creative insurance solutions, it delivers world-class healthcare to millions in India. Western healthcare leaders could adopt similar strategies, including task-shifting, centralised procurement, and scalable insurance models, to lower costs and improve access, especially for underserved populations. Telemedicine and preventive care, both key elements of Shetty’s model, could also play transformative roles in making healthcare more sustainable and inclusive. By embracing these innovations, Western healthcare systems could overcome many of the challenges outlined in the Darzi report, ensuring more equitable and accessible care for all.
view in full page
  • Navigating the dynamic MedTech landscape demands agility, adaptability, and the ability to manage regulatory shifts, global crises, and rapid technological advancements
  • Leaders must blend forward-thinking with strategic focus, ensuring R&D efforts align with emerging healthcare trends and patient needs
  • Inspiring cross-functional collaboration is important and requires cultivating a culture rooted in accountability, innovation, and ethical responsibility
  • MedTech executives must drive innovation while maintaining rigorous regulatory compliance to protect patient safety and uphold corporate integrity
 
Shaping the Future: MedTech Leadership in a Fast-Changing World

Leading a well-established MedTech company requires a blend of vision, technical expertise, regulatory understanding, agility, and emotional intelligence. While financial acumen is fundamental, what sets exceptional executives apart is their ability to navigate the complexities of healthcare, champion innovation, and maintain a strong ethical foundation. These individuals are not just driving their companies toward commercial success; they are actively shaping the future of healthcare by delivering innovative products that enhance patient outcomes and push the boundaries of medical science.

Cultivating these qualities helps ensure that organisations stay competitive, compliant, and focused on creating real value for patients and healthcare systems. As companies navigate an era defined by rapid technological advancements, shifting regulations, and evolving patient expectations, the ability to lead with integrity and strategic foresight becomes ever more critical. With the right mindset, MedTech executives can not only thrive in this fast-paced environment but also leave a lasting impact on the industry and the future of healthcare.

 
In this Commentary

This Commentary highlights seven key leadership capabilities essential for success in large MedTech companies. With rapid technological advancements, shifting regulations, and increasing demands for better patient outcomes, leaders must balance innovation with regulatory compliance. We emphasise the need for visionary thinking, strategic focus, regulatory expertise, technical knowledge, and emotional intelligence. By cultivating collaboration, adaptability, and ethical responsibility, leaders can steer organisations through disruption, navigate global markets, and drive impactful medical technologies that improve patient outcomes and ensure corporate success.
 
1. Visionary Thinking with a Strategic Focus
 
An effective MedTech executive thrives by combining visionary thinking with strategic execution. Looking beyond the present landscape can open opportunities to anticipate advancements in medical technologies, shifts in healthcare delivery models, and evolving expectations from patients and providers. In a sector driven by innovation, those who can envision the future of healthcare and identify how their companies can contribute meaningfully are well-positioned for success.

Yet, vision alone will not get the job done. Translating ambitious ideas into actionable strategies is essential. This involves setting clear corporate goals, allocating resources wisely, and building the infrastructure to support both immediate operational success and long-term innovation. Balancing growth ambitions with a disciplined approach to risk management and regulatory compliance is especially important in the highly regulated MedTech industry.

Effective portfolio management also plays a role. With a diverse range of products - from medical devices to diagnostic tools - focusing on research and development (R&D) projects that align with both the company’s strengths and emerging healthcare needs is crucial. An understanding of the science behind MedTech and the market forces shaping the industry can positively influence where to invest for future success.
 
2. Mastery of Regulatory and Compliance Issues

Navigating regulatory frameworks presents a challenge in the MedTech industry. With agencies like the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) imposing rigorous requirements for product approval, quality control, and post-market surveillance, understanding these environments is essential. The ability to anticipate policy changes and ensure ongoing compliance can impact a company's success.

Beyond market entry, regulatory mastery helps protect a company's reputation. Ensuring that all departments - particularly R&D, manufacturing, and quality assurance - adhere to strict standards is crucial for safeguarding patient safety and product efficacy. Non-compliance risks fines, product recalls, and reputational damage making a strong grasp of regulatory issues indispensable.
In a global market, navigating international regulations adds another layer of complexity. For instance, the European Medical Device Directive (MDD) requires different compliance measures than those of the FDA in the US. Forward-thinking approach involves preparing teams to meet diverse regulatory demands and working closely with legal, regulatory affairs, and quality management professionals to foster a culture of proactive compliance.
You might also like:
 
3. Technical Savvy and a Commitment to Innovation
 
Innovation is the lifeblood of the MedTech sector. Executives at the helm of large companies benefit from a strong grasp of the technologies driving their products, as well as staying attuned to advancements in medical science and digital health. Staying informed about cutting-edge developments like artificial intelligence (AI), machine learning, robotics, and 3D printing is essential, as these innovations are shaping the future of medical devices and diagnostics.

Encouraging a culture of innovation means fostering an environment where teams can experiment, collaborate across disciplines, and take calculated risks. This atmosphere of exploration allows R&D teams to push boundaries and iterate quickly. Success in this space often involves investing in talent, infrastructure, and strategic partnerships. Collaborating with academic institutions, start-ups, technology companies, or healthcare providers can spark the development of breakthrough technologies and expand a company’s capabilities.

Balancing innovation with regulatory demands is equally important. With MedTech products directly impacting patient health, ensuring that innovations undergo thorough testing and validation is critical. Striking the right balance between speed and safety ensures that new technologies are brought to market efficiently without compromising patient wellbeing.
 
4. Customer-Centricity and Patient Outcomes Focus
 
In today's healthcare ecosystem, MedTech companies are increasingly accountable for the outcomes their products deliver, not just for the products themselves. A strong focus on customer-centricity - whether the customer is a healthcare provider, patient, or payer - has become essential. Shifting priorities toward products and services that improve patient outcomes requires an understanding of end-users, from surgeons operating complex devices to patients managing chronic conditions at home.

Developing solutions that provide real-world benefits involves actively engaging healthcare professionals and patients throughout the product lifecycle, from concept through post-market evaluation. This approach ensures that offerings are not only innovative but also address genuine needs in the clinical setting.

As value-based healthcare models gain traction, with reimbursement increasingly tied to patient outcomes, demonstrating both clinical and economic value is critical. This means providing robust clinical evidence while collaborating with healthcare providers, payers, and policymakers to showcase how MedTech solutions improve patient care and reduce overall healthcare costs.
 
5. Agility in Decision-Making and Crisis Management
 
The MedTech industry is characterised by constant change, driven by rapid technological advancements, evolving regulatory requirements, and unexpected challenges like global health crises. Navigating these complexities demands agility in decision-making, allowing organisations to pivot quickly and remain resilient during periods of uncertainty.

This agility comes from a blend of strategic foresight and operational flexibility. Staying ahead of emerging trends and risks, making informed decisions in real time, and adjusting plans as circumstances evolve are all important. For instance, during the COVID-19 pandemic, many MedTechs shifted their focus to produce essential supplies like ventilators and personal protective equipment  (PPE). This involved reallocating resources, adapting supply chains, and safeguarding the workforce - all while ensuring regulatory compliance.
You might also like:

Reimagining Boards
Effective crisis management also plays a role. Whether facing product recalls, quality issues, regulatory challenges, or broader industry disruptions, the ability to respond swiftly is essential. Clear communication, decisive action, and maintaining the trust of key stakeholders - including employees, healthcare providers, patients, and investors - are crucial in navigating crises successfully.
6. Emotional Intelligence

In the MedTech industry, effective leadership goes beyond strategic decision-making and technical expertise - it also requires emotional intelligence and an ability to lead teams. Inspiring and motivating teams is key to fostering a culture of collaboration, innovation, and accountability, especially in a field where success depends on cooperation between engineers, scientists, regulatory experts, and business professionals.

Emotional intelligence plays a role in this dynamic, enabling self-awareness, empathy, and the ability to manage emotions both personally and within teams. Those who exhibit strong emotional intelligence can build stronger relationships, navigate conflicts with ease, and cultivate a positive organisational culture. This also enhances their ability to communicate vision and goals effectively, uniting teams around a shared purpose.

In larger MedTech companies, managing diverse and geographically dispersed teams requires exceptional communication skills and the capacity to foster cohesion and shared responsibility. Encouraging diversity, equity, and inclusion is also critical, as varied perspectives contribute to stronger problem-solving and drive innovation forward.
 
7. Ethical Integrity and Corporate Responsibility

Given the direct impact MedTech products have on patient health, ethical integrity is essential. Ensuring that corporations uphold the highest ethical standards across all operations - from R&D to marketing - is crucial. This means maintaining transparency in clinical trials, avoiding conflicts of interest, and committing to honest and transparent marketing practices that present both the benefits and risks of products accurately.

Beyond ethics, corporate responsibility also involves sustainability and social impact. MedTech companies must acknowledge their broader role in society, not only in improving health outcomes but also in reducing their environmental footprint and contributing to social good. Manufacturing processes should be assessed for their environmental impact, with efforts made to minimise carbon emissions. Additionally, engaging in corporate social responsibility (CSR) initiatives that promote healthcare access in underserved communities is essential for fostering global health equity.

Maintaining the trust of stakeholders - whether healthcare providers, patients, regulators, or investors - depends on a commitment to ethical practices. In an industry where safety and efficacy are non-negotiable, safeguarding trust is vital for protecting both a company’s reputation and its long-term success.

 
Takeaways

In today's MedTech landscape, financial acumen is no longer a differentiator; it is a baseline requirement. What truly sets leaders apart is their ability to navigate an era defined by rapid technological change and global complexity. The future of MedTech leadership hinges on understanding, embracing, and leveraging new technologies to drive meaningful innovation while maintaining the highest standards of regulatory compliance and patient safety.

The seven leadership traits outlined in this Commentary - visionary thinking, regulatory mastery, technical savvy, customer-centricity, agility, emotional intelligence, and ethical integrity - are more critical than ever. These qualities empower leaders to steer their organisations through disruption, inspire cross-functional teams, and deliver cutting-edge solutions that meet market demands and improve patient outcomes.

In this new era, MedTech executives must go beyond the basics of finance and operations. They must be architects of the future, blending strategic foresight with a deep understanding of the technologies that are reshaping the industry. By fostering a culture of innovation, accountability, and ethical responsibility, these leaders will not only ensure corporate success but also make a lasting, transformative impact on global healthcare.
view in full page

In the diagnosis and treatment of brain disorders, neurology is an evolving medical field. Neurology doctors are making breakthroughs every year. Visit the best neurologist in Downtown Brooklyn to treat your recurring headaches. Our specialists can identify a simple headache as a sign of a more serious disease. Trust your stroke doctor at Century Medical and Dental.

 

The human brain is extraordinary. Even though you use it for every part of your life, many aspects of brain functions are still unknown. Neurology doctors diagnose and treat the problems that occur in your brain, spinal cord and peripheral nerves, which make up your nervous system. These treatments can improve the quality of your life immeasurably.


If you’re suffering from headaches or migraines, our neurologist can help. Tingling sensations in your limbs can often be treated successfully. And if you think you have symptoms of other neurological problems like Parkinson’s disease or Alzheimer’s, your primary care physicians can discuss your options with you.

Century Medical & Dental Center
2315 3rd Ave,
New York, NY 10035
Office Tel # (212) 540-5020

Web Address: https://www.centurymedicaldental.com/ 

https://www.centurymedicaldental.com/harlem-upper-manhattan-10035/ 

Google Maps: https://maps.app.goo.gl/5ojNrkimAc4PYK6g7 

https://plus.codes/87G8R337+JV New York

Nearby Locations:
Harlem, Upper Manhattan, Manhattan Valley, Upper West Side, Upper East Side, Yorkville, Randalls Island, Port Morris, Mott Haven, South Bronx
10025, 10026, 10027, 10028, 10035, 10451, 10454, 10455

Working Hours:
Monday: 8:00 am - 6:00 pm
Tuesday: 8:00 am - 6:00 pm
Wednesday: 8:00 am - 6:00 pm
Thursday: 8:00 am - 6:00 pm
Friday: 8:00 am - 6:00 pm
Saturday: Closed
Sunday: 8:00 am - 6:00 pm

Payment: cash, check, credit cards.

view in full page

Optometrists are eye doctors who have earned their Doctor of Optometry (O.D.) degree. Optometrists examine your eyes for health and vision problems and work to fix refractive issues. Refractive issues happen when light entering through the lens of your eye doesn’t bend correctly. Optometrists can also prescribe eyeglasses or contact lenses.
Ophthalmologists are medical doctors (M.D.) or doctors of osteopathic medicine (D.O.) who specialize in caring for the eyes and vision. They are trained in eye exams, identifying and treating disease, prescribing medication, and performing eye surgery. Ophthalmology specialists can also prescribe eyeglasses and contact lenses, but they often deal with disease diagnosis and treatment.

Century Medical & Dental Center
2315 3rd Ave,
New York, NY 10035
Office Tel # (212) 540-5020

Web Address: https://www.centurymedicaldental.com/ 

https://www.centurymedicaldental.com/harlem-upper-manhattan-10035/ 

Google Maps: https://maps.app.goo.gl/5ojNrkimAc4PYK6g7 

https://plus.codes/87G8R337+JV New York

Nearby Locations:
Harlem, Upper Manhattan, Manhattan Valley, Upper West Side, Upper East Side, Yorkville, Randalls Island, Port Morris, Mott Haven, South Bronx
10025, 10026, 10027, 10028, 10035, 10451, 10454, 10455

Working Hours:
Monday: 8:00 am - 6:00 pm
Tuesday: 8:00 am - 6:00 pm
Wednesday: 8:00 am - 6:00 pm
Thursday: 8:00 am - 6:00 pm
Friday: 8:00 am - 6:00 pm
Saturday: Closed
Sunday: 8:00 am - 6:00 pm

Payment: cash, check, credit cards.

view in full page

Nephrology is a specialty that offers nonsurgical interventions for kidney problems. Your nephrologist in Brooklyn is part of a larger practice that provides complete care for you and your family. While nephrology doctors provide nonsurgical treatments, your nephrology doctor can refer you to a doctor for surgery when it comes to weighing a nephrologist vs. urologist.

Nephrology is a medical specialty focused on the study of kidney function and diseases. A nephrology doctor, or nephrologist, diagnoses, treats and manages kidney problems, including kidney stones, renal failure and advanced disorders like cancer. A nephrologist in Brooklyn could save your life someday. Come see our primary care physician to get evaluated and referred to a nephrologist if necessary.
Since hypertension and obesity contribute significantly to kidney diseases, specialized kidney-friendly diets are becoming more popular.
Nephrologist doctors who stay current about managing renal disorders turn to diet as a natural remedy. Ask your doctor how changing your diet can help strengthen your kidneys.

Century Medical & Dental Center
200 Livingston Street
Brooklyn, NY 11201
(718) 522-3399
Web Address: https://www.centurymedicaldental.com/ 

Office Location: https://www.centurymedicaldental.com/downtown-brooklyn-ny-11201/ 

Our locations on the map:
https://goo.gl/maps/C2L9GjvHdnt7SFhJ9 

https://plus.codes/87G8M2Q7+VF Brooklyn

Nearby Locations:
Downtown Brooklyn | Clinton Hill | Gowanus | Cobble Hill | Columbia Street Waterfront District
11201, 11217 | 11238, 11205 | 11217 | 11231

Working Hours:
Monday: 8 am - 9 pm
Tuesday: 8 am - 9 pm
Wednesday: 8 am - 9 pm
Thursday: 8 am - 9 pm
Friday: 8 am - 9 pm
Saturday: 8 am - 6 pm
Sunday: 9 am - 5 pm

Payment: cash, check, credit cards.

view in full page

Podiatry is the medical specialty that treats your feet and ankles. Considering the weight they bear, your feet are small compared to the rest of your body. If you experience foot pain or other problems, consult the best podiatrist in Brooklyn for diagnosis and treatment. Your foot doctor is trained and skilled in identifying problems and choosing the most appropriate treatment option.

  • Note: Podiatrists at Century Medical and Dental Center with offices in Downtown Brooklyn, Flatbush, Gravesend Fort Greene, and Midtown Manhattan accept all major insurance plans, including Medicare, Medicaid, HIP, Emblemhealth, GHI, MetroPlus, and Fidelis. Our top-rated doctors provide a full range of medical procedures and are among the best podiatrists in the region.


Your feet and ankles comprise 26 bones and 33 joints. They contain many more muscles, ligaments, and tendons. Everything must be in excellent working order for you to stand, balance, walk, and run.
Yet, your feet are subject to a lot of abuse as you age. And you may ignore them as part of your usual self-care regimen. As a result, your feet are more prone to injury and wear and tear as you age. The top podiatrist takes care of your feet and ankles, keeping you active and moving. See our
primary care physicians for proper diagnosis, evaluation, and referral to a foot doctor.

Century Medical & Dental Center
200 Livingston Street
Brooklyn, NY 11201
(718) 522-3399

Web Address: https://www.centurymedicaldental.com/ 

Office Location: https://www.centurymedicaldental.com/downtown-brooklyn-ny-11201/ 

Our locations on the map:

https://goo.gl/maps/C2L9GjvHdnt7SFhJ9 

https://plus.codes/87G8M2Q7+VF Brooklyn

Nearby Locations:
Downtown Brooklyn
Downtown Brooklyn | Clinton Hill | Gowanus | Cobble Hill | Columbia Street Waterfront District
11201, 11217 | 11238, 11205 | 11217 | 11231

Working Hours:
Monday: 8 am - 9 pm
Tuesday: 8 am - 9 pm
Wednesday: 8 am - 9 pm
Thursday: 8 am - 9 pm
Friday: 8 am - 9 pm
Saturday: 8 am - 6 pm
Sunday: 9 am - 5 pm

Payment: cash, check, credit cards.

view in full page
  • The intersection of antimicrobial resistance (AMR) and climate change impacts human health, ecosystems, and socio-economic stability
  • AMR complicates disease treatment and medical procedures, while climate change alters disease dynamics, expands pathogen ranges, and threatens clean water and sanitation
  • Combined, AMR and climate change strain healthcare systems, exacerbate health disparities, and threaten food security, especially for vulnerable communities
  • Coordinated global responses integrating health, environmental, and developmental perspectives are needed to promote resilience, sustainability, and improved health outcomes
 
Antimicrobial Resistance and Climate Change: A Global Crisis
 
On September 26, 2024, the United Nations General Assembly will convene a High-Level Meeting on antimicrobial resistance (AMR) in New York. Drug-resistant infections transcend borders, making it impossible for any single country to tackle AMR on its own. This meeting offers an opportunity for global leaders to collaboratively address the threat that AMR poses to public health, food security, and the attainment of the 2030 Sustainable Development Goals. According to recent estimates, ~1.3m deaths worldwide in 2019 were caused by drug-resistant infections. If current trends continue, by 2050, AMR is projected to cause ~10m deaths annually, with costs to the global economy >US$100trn. Furthermore, this trend could force ~24m more people into extreme poverty over the next decade. These figures emphasise the threat posed by AMR, far surpassing the impact of COVID-19.

In the landscape of contemporary global health challenges, two significant and interconnected threats demand attention: AMR and climate change. These issues, though distinct in nature, share an interconnectedness that magnifies their collective impact on human health, ecological integrity, and socio-economic stability.

AMR poses a growing risk as microbes evolve to withstand the drugs designed to combat them. This phenomenon complicates the treatment of infectious diseases and jeopardises the effectiveness of medical procedures ranging from surgeries to cancer treatments. Concurrently, climate change exacerbates these challenges by altering disease dynamics, expanding the geographical range of vectors and pathogens, and compromising access to clean water and sanitation: fundamental prerequisites for health.

Moreover, the convergence of AMR and climate change intensifies the strain on vulnerable populations, exacerbates health disparities, and threatens food security and agricultural productivity. These issues transcend national borders, necessitating coordinated global responses that integrate health, environmental, and developmental perspectives. Hence, the UN meeting in September 2024, which marks only the second such gathering in its 79-year history. By recognising and addressing the interconnectedness of these dual crises, we can promote resilience, support sustainable development, and safeguard the wellbeing of present and future generations worldwide.

 
Understanding Antimicrobial Resistance

AMR refers to the ability of microorganisms - primarily bacteria, viruses, fungi, and parasites - to evolve and withstand the effects of antimicrobial agents, including antibiotics, antivirals, and antifungals. While this evolutionary process is natural, human activities have accelerated it, particularly through the overuse and misuse of antimicrobial drugs in human medicine, agriculture, and veterinary practices.
The consequences of AMR are extensive and multifaceted. In healthcare settings, infections that were once treatable with common antibiotics are becoming increasingly difficult, if not impossible, to cure. This resistance leads to prolonged illnesses, longer hospital stays, higher medical costs, and increased mortality rates. Moreover, the rise of multidrug-resistant strains poses a threat to medical procedures, such as surgeries, chemotherapy, and organ transplants, which rely on effective antimicrobial prophylaxes and treatment.
You might also like:
 
Beyond healthcare, AMR threatens food security and safety. The widespread use of antimicrobials in agriculture to promote growth and prevent disease in livestock leads to the development of resistant bacteria that can enter the food chain. These resistant strains can then be transmitted to humans through the consumption of contaminated food, direct contact with animals, or environmental pathways, such as water and soil.

The environmental impact of AMR is also significant. Antimicrobial residues from pharmaceuticals, agricultural runoff, and waste from healthcare facilities can persist in the environment, promoting the development and spread of resistance among environmental microorganisms. This environmental reservoir of resistance genes can transfer to human and animal pathogens, further complicating the management of infectious diseases.

Addressing AMR requires a comprehensive and coordinated approach, including the promotion of responsible antimicrobial use, investment in research and development (R&D) of new drugs, and the implementation of robust surveillance systems to monitor resistance patterns. Public awareness and education on the prudent use of antimicrobials are equally important in mitigating this global threat.

 
The Rise of Climate Change

Climate change presents a distinct and significant set of challenges to global ecosystems and human societies. Primarily driven by anthropogenic activities such as the burning of fossil fuels, deforestation, and industrial emissions, climate change manifests in rising global temperatures, altered precipitation patterns, more frequent and severe extreme weather events, and sea-level rise. These changes disrupt ecosystems, endanger biodiversity, and threaten human livelihoods, particularly in vulnerable communities with limited resources to adapt.

The implications of climate change are far-reaching and complex. Increased risks of natural disasters, such as hurricanes, floods, and wildfires, lead to loss of life, property damage, and economic instability. Altered precipitation patterns can result in prolonged droughts in some regions and excessive rainfall in others, affecting agricultural productivity and leading to food and water insecurity. As these climatic conditions shift, they also change the habitats and behaviours of disease vectors like mosquitoes and ticks, altering disease patterns and potentially introducing new health threats to populations unaccustomed to such risks.

These environmental shifts have indirect effects on human health, exacerbating existing health disparities and amplifying the burden on healthcare systems already strained by other challenges, such as AMR. The displacement of populations due to rising sea levels, extreme weather events, and deteriorating living conditions further compounds these issues, creating climate refugees who require humanitarian assistance and healthcare support.

 
Convergence of Threats

The convergence of AMR and climate change amplifies their individual impacts, creating a scenario where each phenomenon exacerbates the effects of the other. This interplay is illustrated through several mechanisms. Climate change significantly alters ecological systems, influencing the geographic distribution and prevalence of infectious diseases. Warmer temperatures, for example, can expand the range of disease vectors like mosquitoes, leading to increased transmission of diseases such as malaria and dengue fever. In a context of AMR, where effective treatments for these diseases are diminishing, the burden on healthcare systems and affected populations intensifies, making it harder to manage and control outbreaks.

You might also like:

The Shifting Landscape of ESG Reporting in the MedTech Industry

Climate change-induced extreme weather events, such as hurricanes, floods, and heatwaves, pose risks to healthcare infrastructure and services. Disruptions in healthcare provision can compromise infection control measures and lead to increased transmission of resistant pathogens within healthcare settings. Moreover, displaced populations and compromised living conditions post-disaster create environments conducive to disease outbreaks, further challenging already strained healthcare resources. The vulnerability of healthcare infrastructure to climate-related disruptions emphasises the need for resilient systems that can withstand and adapt to these changes.
Agriculture is both a contributor to and influenced by climate change. Changing weather patterns impact crop yields and livestock production, leading to shifts in agricultural practices, including the increased use of antimicrobials in animal husbandry to prevent disease and promote growth under stressful conditions. Global antimicrobial use in food animal production was ~63,151 tons in 2010 and is expected to increase by ~67% to ~105,596 tons by 2030. Around 80% of food-producing animals and birds receive medication for at least part of their lives. Antimicrobials used in food animals constitute ~80% of the total antimicrobial consumption in the US each year. Most of the global rise (~67%) in antimicrobial use is driven by the growing population of animals raised for food.

Increased temperatures and altered precipitation patterns also impact food safety, with potential implications for foodborne illnesses caused by resistant pathogens. These agricultural shifts not only shape food security but also introduce resistant bacteria into the food chain and the environment, posing further risks to human health.

Climate change also affects global trade routes and patterns, influencing the movement of goods and people. This interconnectedness facilitates the spread of infectious diseases and resistant microbes across borders, complicating efforts to contain AMR on a global scale. The emergence of new pathogens and resistant strains in different regions points to the need for coordinated international efforts to address these interconnected challenges. The combined threats of AMR and climate change necessitate comprehensive, integrated strategies that involve local, national, and global collaboration to mitigate their multifaceted impacts. Addressing these interconnected challenges is essential for promoting public health, environmental sustainability, and global socio-economic stability.

 
Projected Impact and Future Scenarios

The projected impact of the combined threats of AMR and climate change paints a distressing picture for global health and wellbeing. As AMR reduces the effectiveness of existing treatments, healthcare systems face increased pressure to develop new antimicrobial agents. However, the pipeline for new antibiotics is limited due to scientific and economic challenges. Climate change-induced health crises further strain these systems, potentially overwhelming their capacity to respond effectively. The economic burden of AMR is substantial. The World Bank estimates that AMR could result in ~US$1trn additional healthcare costs by 2050, and ~US$1trn to ~US$3.4trn gross domestic product (GDP) losses per year by 2030. Climate change exacerbates these costs through disruptions to agricultural productivity, healthcare expenditures, and labour productivity. Socio-economic disparities are likely to widen as vulnerable populations bear the brunt of these combined impacts, leading to increased poverty and reduced access to essential services.

Ecosystems, which provide services such as water purification, carbon sequestration, and biodiversity maintenance, are also under threat. Climate change and AMR compromise these services, undermining environmental resilience and exacerbating the vulnerability of both natural and human systems. The degradation of ecosystems can lead to the loss of biodiversity, further disrupting ecological balance and increasing the spread of resistant pathogens. As these environmental and health challenges intensify, the global community faces a future where traditional methods of disease control and prevention may no longer be effective, necessitating innovative approaches and robust international cooperation to safeguard human health and maintain ecological stability.

 
Mitigation and Adaptation Strategies

Tackling the intertwined challenges of AMR and climate change requires well-coordinated, comprehensive strategies implemented at local, national, and global levels. Enhanced surveillance and monitoring systems are important for tracking resistant pathogens and infectious diseases, allowing for early detection and response. Integrating environmental and climate data into these surveillance frameworks provides a more detailed understanding of disease dynamics and antimicrobial use patterns, helping to identify and address emerging threats more effectively.

Promoting the sustainable use of antimicrobials in human medicine, agriculture, and veterinary practices is essential to mitigate the spread of resistance. This involves advocating for responsible prescribing and use, implementing regulations to curb overuse and misuse, and promoting alternative practices such as vaccination and improved hygiene. These measures can reduce reliance on antimicrobial agents and slow the development of resistance.

Building resilient healthcare infrastructure capable of withstanding climate-related disruptions is critical for maintaining health services during crises. This includes enhancing infection prevention and control measures, improving disaster preparedness, and ensuring access to essential healthcare services during and after extreme weather events. Strengthening healthcare systems' capacity to cope with both AMR and climate impacts can prevent service disruptions and manage disease outbreaks more effectively.

Mitigating climate change through emissions reduction and adaptation strategies is crucial for reducing the frequency and severity of climate-related health impacts. Investing in renewable energy sources, promoting sustainable agricultural practices, and developing resilient urban planning are integral to these efforts. Such investments address climate change and support broader efforts to combat AMR by reducing environmental pressures that contribute to resistance.

International collaboration and governance frameworks are indispensable in addressing the global challenges posed by AMR and climate change. These frameworks should promote information sharing, capacity building, and equitable access to resources. Global health agencies, such as the World Health Organisation (WHO) and the Food and Agriculture Organisation (FAO), play pivotal roles in facilitating collaboration and setting international standards for antimicrobial use and climate resilience.

An approach that integrates health, environmental, and socio-economic considerations is necessary to effectively tackle these threats. By investing in R&D, promoting sustainable practices, and fostering international cooperation, the global community can develop strategies to mitigate the impacts of AMR and climate change. Such an approach will help safeguard public health, enhance ecological stability, and ensure socio-economic resilience, ultimately securing a healthier and more sustainable future for all.

 
Takeaways

The interconnected threats of AMR and climate change demand urgent and coordinated global action. Each poses challenges to human health, the environment, and socio-economic stability, but their convergence magnifies the impact, creating a complex web of risks that transcends borders and disciplines. Addressing these threats requires integrated strategies that recognise their interconnectedness, fostering resilience through sustainable practices, robust healthcare systems, and international cooperation. By enhancing surveillance, promoting responsible antimicrobial use, and mitigating climate change, we can build a future that not only curbs the rise of resistance and mitigates environmental degradation but also strengthens the foundations of global health and ecological integrity. The path forward necessitates innovation, investment, and a unified global commitment to safeguard the wellbeing of current and future generations. Let us hope that the United Nations General Assembly meeting in September 2024 to address this issue will energise international responses.
view in full page